The Nonmelanoma Skin Cancer market is expected to experience substantial growth from 2024 to 2034, driven by increasing ...

Patients with a rare disease called mucous membrane pemphigoid are at risk of developing squamous cell carcinoma and basal cell carcinoma, finds a new study.

Findings from a phase 1 trial demonstrate that silmitasertib shows potential for the treatment of patients with advanced ...

As I've been looking into the cost of the best cell phone plans for a decade now, I'm extremely familiar with what different carriers charge for different plans and how much data you get in ...

in the treatment of basal cell carcinoma (BCC), with positive data outcomes. The study included patients who had relapsed after standard therapies and had no other treatment options. Among them, three ...

Therefore, Senhwa will actively pursue licensing possibilities while carefully evaluating CX-4945's potential as a monotherapy or in combination with the second-line immunotherapy Libtayo. The company ...

Notably, 27.3% (6 patients) had also failed second-line PD-1 inhibitors such as Libtayo or Keytruda ... in the Treatment of Basal Cell Carcinoma(BCC), with positive data outcomes. The study included ...

Senhwa Biosciences, Inc. (TPEx: 6492), a new drug development company focusing on first-in-class therapeutics for oncology, rare diseases, and infectious diseases, today announced that the completion ...

Therefore, Senhwa will actively pursue licensing possibilities while carefully evaluating CX-4945's potential as a monotherapy or in combination with the second-line immunotherapy Libtayo.